Literature DB >> 7559437

Orphan nuclear receptor HNF-4 binds to the human coagulation factor VII promoter.

D Erdmann1, J Heim.   

Abstract

The human coagulation protease factor VII plays a pivotal role in the initiation of the coagulation cascade by both the extrinsic and the intrinsic pathway. Although the gene, encoding factor VII, is expressed predominantly in the liver, the mechanisms underlying this tissue-specific expression have not been elucidated. In this study, we have analyzed the contribution of 5 kilobases upstream of the ATG translational initiation codon upon hepatic factor VII gene transcription. Transient transfection assays of a set of nested deletions in both liver and non-liver cell lines, HepG2 and HeLa respectively, indicate that several regions are involved in liver-specific expression. A slight negative effect on factor VII promoter activity in HepG2 cells is mediated by sequences upstream of position -1212. DNase I protection experiments reveal six footprints, FPVII1 through FPVII6, within the proximal 714 base pairs but a minimal promoter of 165 base pairs containing only FPVII3-6 is sufficient to confer liver-specific expression in HepG2 cells. Interestingly, FPVII6, at position -14 to +10 on the sense strand, would indicate that an as yet unknown transcription factor covers the ATG translational initiation codon. Gel retardation experiments show that the liver-enriched transcription factor HNF-4 binds specifically to footprint FPVII4 at position -71 to -49. Furthermore, a T --> A transversion, that in the HNF-4 binding site of factor IX causes a severe bleeding disorder, was introduced into the HNF-4-binding site of factor VII and reduced promoter activity by 20-50%. Coordinate HNF-4-mediated regulation of several blood protease genes as well as genes involved in lipid metabolism might account for the positive correlation of these factors with increased risk of occlusive heart diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559437     DOI: 10.1074/jbc.270.39.22988

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Hepatic function in a family with a nonsense mutation (R154X) in the hepatocyte nuclear factor-4alpha/MODY1 gene.

Authors:  T Lindner; C Gragnoli; H Furuta; B N Cockburn; C Petzold; H Rietzsch; U Weiss; J Schulze; G I Bell
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

2.  Hepatocyte nuclear factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases.

Authors:  Shiro Koizume; Naho Yokota; Etsuko Miyagi; Fumiki Hirahara; Yoshiyasu Nakamura; Yuji Sakuma; Akira Yoshida; Yoichi Kameda; Eiju Tsuchiya; Wolfram Ruf; Yohei Miyagi
Journal:  Mol Cancer Res       Date:  2009-12-08       Impact factor: 5.852

Review 3.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

4.  Co-operation of the transcription factor hepatocyte nuclear factor-4 with Sp1 or Sp3 leads to transcriptional activation of the human haem oxygenase-1 gene promoter in a hepatoma cell line.

Authors:  Shigeru Takahashi; Naomi Matsuura; Takako Kurokawa; Yuji Takahashi; Takashi Miura
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

Review 5.  Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  Biomark Cancer       Date:  2015-09-06

Review 6.  The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm.

Authors:  Keren Borensztajn; Jan H von der Thüsen; Maikel P Peppelenbosch; C Arnold Spek
Journal:  J Cell Mol Med       Date:  2009-11-28       Impact factor: 5.310

7.  MiRNA-Based Regulation of Hemostatic Factors through Hepatic Nuclear Factor-4 Alpha.

Authors:  Salam Salloum-Asfar; Ana B Arroyo; Raúl Teruel-Montoya; Nuria García-Barberá; Vanessa Roldán; Vicente Vicente; Constantino Martínez; Rocío González-Conejero
Journal:  PLoS One       Date:  2016-05-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.